 |
|
|
|
Year 2018 - Volume 38, Number 3
|
.jpg)
|
Randomized controlled clinical trial of ketoanalogues supplementation in dogs with chronic kidney disease, 38(3):489-495
|
ABSTRACT.- Liguori T.T.A., Melchert A., Takahira R.K., Ramos P.R.R., Padovani C.R., Barreti P. & Guimarães-Okamoto P.T.C. 2018. Randomized controlled clinical trial of ketoanalogues supplementation in dogs with chronic kidney disease. [Estudo clínico randomizado controlado da suplementação de cetoanálogos em cães com doença renal crônica.] Pesquisa Veterinária Brasileira 38(3):489-495. Departamento de Clínica Veterinária, Faculdade de Medicina Veterinária e Zootecncia, Universidade Estadual Paulista, Av. Bento Lopes 679, Distrito Rubião Júnior, Botucatu, SP 18618-970, Brazil. E-mail: tacia.liguori@usp.br
The objective was to verify the effectiveness of ketoanalogues in dogs with Chronic Kidney Disease (CKD) stage 3. Controlled randomized clinical trial was performed with twenty dogs with CKD stage 3. Animals were subjected to: Group 1 (control): conventional therapy (CT) for CKD; Group 2: CT and 60mg/kg, OA, q48h of keto-supplementa; Group 3, CT and 60mg/kg, OA, q24h of keto-supplementa; and Group 4, CT and 120mg/kg, OA, q12h of keto-supplementa. All dogs received canine renal diet. Animals were evaluated at the beginning of therapy and after 15 and 30 days. Complete blood count (CBC), serum urea, creatinine, phosphorus, calcium, potassium and sodium and urine protein/creatinine (UPC) ratio were analyzed. The use of ketoanalogues in dogs with CKD stage 3 during the period of 30 days showed no efficacy, in any of the studies dosages, to improve signs and symptoms of the disease, improve the values of CBC, reduce serum urea and creatinine, normalize electrolytes or reduce UPC. It is concluded that the use of ketoanalogues does not impact the clinical outcomes in dogs with CKD stage 3. |
| |
|
|
| |
|
|
